Losartan potassium

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Losartan potassium

CAS No. : 124750-99-8

MCE 国际站：Losartan potassium

产品活性：Losartan potassium (DuP-753 potassium) 是血管紧张素 II 受体 1 型 (AT1)拮抗剂，与血管紧张素 II 与 AT1 的结合竞争，IC₅₀ 为 20 nM。

研究领域：GPCR/G Protein

作用靶点：Angiotensin Receptor

In Vitro: Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC₅₀) is 20 nM. Losartan (40 μM) affects I_SC but prevents the effect of ANGII on I_SC. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone.

In Vivo: Losartan (0.6 g/L, p.o.) -treated Fbn1^C1039G/+ mice show a reduction in distal airspace caliber relative to placebo-treated Fbn1^C1039G/+ animals. The doses of losartan and propranolol are titrated to achieve comparable hemodynamic effects. Analysis of pSmad2 nuclear staining reveals that losartan antagonizes TGF-β signaling in the aortic wall of Fbn1^C1039G/+ mice. Losartan can improve disease manifestations in the lungs, an event that cannot plausibly relate to improved hemodynamics. Losartan (10 mg/kg, intraarterial injection) increases blood angiotensin levels four- to sixfold. Losartan (10 mg/kg, i.p.) increases plasma renin levels 100-fold; plasma angiotensinogen levels decreases to 24% of control; and plasma aldosterone levels are unchanged.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  GPCR/G Protein Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Endocrinology Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  Neurotransmitter Receptor Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Angiogenesis-Related Compound Library  |  Rare Diseases Drug Library  |  Children’s Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Non-steroidal Anti-Inflammatory Compound Library  |  Off-patent Drug Library  |  Antihypertensive Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Angiotensin II human  |  Losartan  |  Telmisartan  |  Valsartan  |  Tranilast  |  A 779  |  Buloxibutid  |  AVE 0991  |  Candesartan  |  Irbesartan  |  YS-49  |  Nitrosoglutathione  |  Olmesartan  |  Olodanrigan  |  PD 123319 ditrifluoroacetate  |  CGP-42112  |  Talfirastide acetate  |  Alamandine  |  Azilsartan medoxomil  |  Angiotensin II 5-valine  |  Sparsentan  |  TRV-120027 TFA  |  Angiotensin III, human, mouse  |  Angiotensin II (3-8), human TFA

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds